Your browser doesn't support javascript.
loading
Cost-effectiveness of the tandem t: Slim X2 with control-IQ technology automated insulin delivery system in children and adolescents with type 1 diabetes in Sweden.
Adolfsson, Peter; Heringhaus, Alina; Sjunnesson, Karin; Mehkri, Laila; Bolin, Kristian.
Afiliación
  • Adolfsson P; Department of Pediatrics, The hospital of Halland Kungsbacka, Kungsbacka, Sweden.
  • Heringhaus A; Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Sjunnesson K; Department of Pediatrics, The hospital of Halland Kungsbacka, Kungsbacka, Sweden.
  • Mehkri L; Department of Pediatrics, The hospital of Halland Kungsbacka, Kungsbacka, Sweden.
  • Bolin K; MedEngine DK ApS, Copenhagen, Denmark.
Diabet Med ; : e15432, 2024 Sep 06.
Article en En | MEDLINE | ID: mdl-39239975
ABSTRACT

AIMS:

The present analysis estimated the cost-effectiveness of treatment with the Tandem t slim X2 insulin pump with Control IQ technology (CIQ) in children with type 1 diabetes in Sweden.

METHODS:

A four-state Markov model and probabilistic sensitivity analyses (PSA) were used to assess the cost-effectiveness of CIQ use compared with treatment with multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII) in conjunction with CGM. Data sources included clinical input data from a recent retrospective, observational study, cost data from local diabetes supply companies and government agencies, and published literature. Outcomes measures were quality adjusted life years (QALYs) at 10, 20 and 30-year time horizons based on cost per QALY and incremental cost-effectiveness ratio (ICER).

RESULTS:

A total of 84 type 1 diabetes children were included (CIQ, n = 37; MDI, n = 19; CSII, n = 28). For all time horizons, the use of CIQ was a dominant strategy (e.g. more effective and less costly) compared with MDI or CSII use 10-year ICER, SEK -88,010.37 and SEK -91,723.92; 20-year ICER, SEK -72,095.33 and SEK -87,707.79; and 30-year ICER, SEK -65,573.01 and SEK -85,495.68, respectively. PSA confirmed that CIQ use was less costly compared with MDI and CSII.

CONCLUSIONS:

Initiation of CIQ use in children with type 1 diabetes is cost-saving, besides previously shown improved glycaemic control, and increased quality of life. Further investigations are needed to more fully elucidate the cost-effectiveness of these technologies in different countries with existing differences in payment models.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Diabet Med Asunto de la revista: ENDOCRINOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Diabet Med Asunto de la revista: ENDOCRINOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Reino Unido